Translational research offers individually tailored treatments for cancer patients

Cancer Journal from Scientific American

Volumn 6, Issue 1, 2000, Pages 2-10

  Bartelink, H ^a   Begg, A C ^a   Coco Martin, J ^a   Van Dijk, M ^a   Moonen, L ^a   Van't Veer, L J ^a   Van De Vaart, P ^a   Verheij, M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CISPLATIN; CYCLIN D1; ESTROGEN RECEPTOR; IDOXURIDINE; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DNA ADDUCT; DRUG POTENCY; DRUG RESEARCH; HUMAN; LABELING INDEX; LUNG CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW;

ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DNA ADDUCTS; HUMANS; NEOPLASMS; RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 0033973067     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Bartelink HB, Kallman RF, Rapacchietta D et al. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of CDDP and irradiation. Radiother Oncol 1986;6:61-74.
2. Schaake-Koning C, Van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
3. Jeremic B, Shibamoto Y, Acimovic L et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900.
4. Calais G, Alfonsi M, Bardet E et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma (ARCORO): preliminary results of the 94-01 study from the French Group of Radiation Oncology for Head and Neck Cancer (GORTEC) [abstract 1484]. Proceedings of the 34th Annual Meeting of the American Society for Clinical Oncology, May 16-19, Los Angeles, CA. J Clin Oncol 1998;17:385a.
5. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
6. Morris M, Eifel PJ, Jiandong L et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340:1137-1143.
7. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
8. Bourhis J, Pignon JP, Designé M et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) loco-regional treatmenr vs same treatment + chemotherapy (CT) [abstract 1487]. Proceedings of the 34th Annual Meeting of the American Society for Clinical Oncology, May 16-19, Los Angeles, CA. J Clin Oncol 1998;17:386a.
9. Robbins KT, Kumar P et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys 1996;38:263-271.
10. Begg AC. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 1990;19: 1183-1189.
11. Terheggen PMAB, Emondt JY, Floot BGJ et al. The correlation between cell killing by cis-diamminedichloroplatinum (II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum (II)-DNA antiserum. Cancer Res 1990;50:3556-3561.
12. Terheggen PM, Dijkman R, Begg AC et al. Monitoring of interaction products of cis-diamminedichlorophatinum (II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum (II) with DNA in cells from platinum-treated cancer patients. Cancer Res 1988; 48:5597-603.
13. Schuster-Uitterhoeve ALJ, Van de Vaart PJM, Schaake-Koning CCE et al. Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer. Eur J Cancer 1996;32A:1314-1319.
14. Van de Vaart PJ, Belderbos J, De Jong D et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; in press.
15. Barton MB, Keane TJ, Gadalla T. The effect of treatment time on tumor control in the radical radiotherapy of laryngeal cancer. Radiother Oncol 1992;23:137-143.
16. Overgaard J, Hjelm-Hansen M, Vendelbo Johansen L et al. Comparison of conventional and split course radiotherapy as primary tteatment in carcinoma of the larynx. Acta Oncol 1988;27:147-152.
17. Fyles A, Keane TJ, Barton M et al. The effect of overall treatment duration in the local control of cervix cancel. Radiother Oncol 1992;25:273-279.
18. Horiot JC, Bontemps P, Van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
19. Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 1997;350:161-165.
20. Horiot JC, Le Fur R, Nguyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiat Oncol 1992;25:231-241.
21. Begg AC, McNally NJ, Shrieve DC et al. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985;6:620-626.
22. Begg AC, Hofland K, van Glabbeke M et al. Predictive value of potential doubling time for radiotherapy of head and neck tumour patients: results from the EORTC cooperative trial 22851. Semin Rad Oncol 1992;1:22-25.
23. Begg AC, Haustermans K, Hart AA et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy out come in head and neck cancer: a multicentre analysis. Radiother Oncol 1999;50:13-23.
24. West CM, Davidson SE, Roberts SA et al. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997;76: 1184-1190.
25. Coco-Martin JM, Begg AC. Potential of radiation-induced chromosome aberrations to predict radiosensitivity in human tumor cells. Int J Radiat Biol 1999; in press.
26. Coco-Martin JM, Begg AC. Detection of radiation-induced chromosome aberrations using fluorescence in situ hybridization in drug-induced premature chromosome condensations of tumor cell lines with different radiosensitivities. Int J Radiat Biol 1997; 71:265-273.
27. Zwijsen RM, Wientjens E, Klompmaker R et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88: 405-415.
28. Zwijsen RM, Buckle RS, Hijmans EM et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998;12:3488-3498.
29. Ling CC, Chen CH, Li WX. Apoptosis induced at different dose rates: implication for the shoulder region of cell survival curves. Radiother Oncol 1994;32:129-136.
30. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995;33: 781-796.
31. 192Ir source. Acta Oncol 1997;36:261-266.
32. IllidgeTM. Radiation-induced apoptosis. Clin Oncol 1998;10:3-13.
33. Meyn RE, Stephens L, Hunter NR et al. Reemergence of apoptotic cells between fractionated doses in irradiated murine tumors. Int J Radiat Oncol Biol Phys 1994;30: 619-624.
34. Rupnow BA, Murtha AD, Alarcon RM et al. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res 1998;58:1779-1784.
35. Hallahan DE, Virudachalam S, Kuchibotla J et al. Membrane-derived second messenger regulates X-ray-mediated tumor necrosis factor alpha gene induction. Proc Natl Acad Sci USA 1994;91: 4897-4901.
36. Haimovitz-Friedman A, Kan C-C, Ehleiter D et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994;180:525-535.
37. Giusti AM, Raimond M, Ravagnan G et al. Human cell membrane oxidative damage induced by single and fractionated doses of ionizing radiation: a fluorescence spectroscopy study. Int J Radiat Biol 1998;74:595-605.
38. Kolesnick R. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 1991;30:1-38.
39. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994;269:3125-3128.
40. Jarvis WD, Kolesnick RN, Fornari FA et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 1994; 91:73-77.
41. Quintans J, Kilkus J, McShan CL et al. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun 1994;202:710-714.
42. Verheij M, Bose R, Lin XH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996;380:75-79.
43. Verheij M, Ruiter GA, Zerp SF et al. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother Oncol 1998a;47:225-232.
44. Verheij M, van Blitterswijk WJ, Bartelink H. Radiation-induced apoptosis: the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol. 1998b;37:575-584.
45. Sawai H, Okazaki T, Yamamoto H et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 1995;270:27326-27331.
46. Chen Y-R, Wang X, Templeton D et al. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. J Biol Chem 1996;271:31929-31936.
47. Zanke BW, Boudreau K, Rubie E et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cisplatinum, UV irradiation or heat. Curr Biol 1996;6:606-613.
48. Shirakabe K, Yamaguchi K, Shibuya H et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 1997;272:8141-8144.
49. Fuks Z, Persaud RS, Alfieri A et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994;54:2582-2590.
50. Frisch SM, Vuori K, Kelaita D et al. A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J Cell Biol 1996; 135:1377-1382.
51. Chmura SJ, Mauceri HJ, Advani S et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C: inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 1997;57:4340-4347.
52. Carter S, Auer KL, Reardon DB et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998;16:2787-2796.
53. Xia Z, Dickens M, Raingeaud J et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270: 1326-1331.
54. Cuvillier O, Pirianov G, Kleuser B et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-803.
55. Jarvis WD, Fornari FA Jr, Auer KL et al. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol 1997;52:935-947.
56. Van Blitterswijk WJ, Hilkmann H, Storme GA. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 1987;22:820-823.
57. Powis G. Anticancer drugs acting against signaling pathways. Curr Opin Oncol 1995;7:554-559.
58. Zhou X, Lu X, Richard C et al. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. J Clin Invest 1996; 98:937-944.
59. Ruiter GA, Zerp SF, Bartelink H et al. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 1999;59:2457-2463.
60. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293-1298.
61. Naja A, Roché H, Mihura J et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: a randomized trial with a 7 years median Mow up [abstract 87]. Radiother Oncol 1997; 43 (suppl 2): S22.
62. Aebi S, Gelber S, Castiglione-Gertsch M et al. Treatment with chemotherapy alone is inadequate for very young women with estrogen receptor positive breast cancer: results from the International Breast Cancer Study Group (IBCSG) Trials I, II, III, IV [abstract 260]. Proceedings of the 35th Annual Meeting of the American Society for Clinical Oncology, May 15-18, 1999, Atlanta, GA.
63. Bartelink H, Rubens RD, Van der Schueren E et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997;15:207-215.
64. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
65. Van Dijk MAJ, Floore AN, Kloppenborg KIM et al. A functional assay in yeast for human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res 1997;57:3478-3485.
66. Bartelink H, Begg A, Coco-Martin J et al. Towards prediction and modulation of treatment response. Radiother Oncol 1999;50:1-11.